VEGFA and neoplasm: By treating the patient with anti-VEGF agents, the VEGF-dependent vessels will be targeted and disrupted, whilst the tumor vessels will be increasingly covered by pericytes; these pericytes have been shown to overexpress FGF2, thereby switching the angiogenic pathway dependency towards FGF2 [62].